| Biogen INC BIOGEN INC ORD SHS | 303.79 / +1.43% |
| Date/Time | 12/06 / 19:26 |
| Chg. / Chg.(%) | 4.29 / +1.43% |
| Bid | - |
| Ask | - |
| Open | 296.68 |
| Previous Close | 299.50 |
| High | 304.00 |
| Low | 296.68 |
| Volume [USD] | 457,834.91 |
| Volume [Units] | 1,645 |
| Price fixings | 23 |
| ISIN | US09062X1037 |
| Security | 0R1B |
| Exchange | London International |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 270.850 |  |
|
| NASDAQ | 300.2600 | |
2,261,355 |
| IEX | 300.34 | |
201,966 |
| Cboe US | 300.28 | |
164,023 |
| London Inter.. | 303.79 |  |
1,645 |
| TradeGate | 272.100 | |
780 |
| Xetra | 273.30 | |
268 |
| Stuttgart | 273.150 | |
202 |
| Vienna Globa.. | 273.40 | |
133 |
| Mexico | 5,860.00 | |
30 |
| Frankfurt | 272.3500 | |
23 |
| München | 268.45 | |
0 |
| Hamburg | 268.50 | |
0 |
| Düsseldorf | 270.00 | |
0 |
| Berlin | 274.60 | |
0 |
| Hannover | 268.50 | |
0 |
| SIX Swiss Ex.. | 232.00 | |
|
| gettex | 272.650 | |
News
- Biogen stocks rise on new Alzheimer drug breakthrough
12/05/2019 / 19:26 - TeleTrader - Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
12/03/2019 / 13:30 - GlobeNewswire - Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)
11/22/2019 / 13:30 - GlobeNewswire - Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
11/21/2019 / 13:30 - GlobeNewswire - AZTherapies Announces Appointment of Ernest D. Penachio as Vice President of Manufacturing Operations and CMC
11/06/2019 / 22:05 - GlobeNewswire
Real-time